Radiotherapy as primary treatment modality

Frontiers of Radiation Therapy and Oncology

Volumn 41, Issue , 2008, Pages 15-25

  Sia, M ^b   Rosewall, T ^b   Warde, P ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; HUMAN; MALE; METHODOLOGY; PATHOLOGY; PROSTATE TUMOR; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 49449098793     PISSN: 00719676     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000139874     Document Type: Conference Paper

References (40)

1. Cooperberg MR, Lubeck DP, Mehta SS, Carroll PR: Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003;170:S21-S25; discussion S26-S27.
2. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Hug EB, Asbell SO, Grignon D: Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-1290.
3. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002;360:103-106.
4. D'Amico AV, Desjardin A, Chung A, Chen MH, Schultz D, Whittington R, Malkowicz SB, Wein A, Tomaszewski JE, Renshaw AA, Loughlin K, Richie JP: Assessment of outcome prediction models for patients with localized prostate carcinoma managed with radical prostatectomy or external beam radiation therapy. Cancer 1998;82:1887-1896.
5. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L: Controversies in prostate cancer radiotherapy: consensus development. Can J Urol 2001;8:1314-1322.
6. Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A: A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:380-385.
7. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D: Determinants of prostate cancer specific survival following radiation therapy during the prostate specific antigen era. J Urol 2003;170:S42-S46; discussion S46-S47.
8. Klotz L: Active surveillance for prostate cancer: for whom? J Clin Oncol 2005;23:8165-8169.
9. Kupelian P, Potters L, Khuntia D, Ciezki JP, Reddy C, Reuther AM, Carlson TP, Klein EA: Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or = 72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Rad Onc Biol Phys 2004;58:25-33.
10. Wallace K, Fleshner N, Jewett M, Basiuk J, Crook J: Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol 2006;24:4158-4162.
11. Lukka H, Pickles T, Morton G, Catton C, Souhami L, Warde P: Prostate cancer radiotherapy 2002: the way forward. Can J Urol 2005;12:2521-2531.
12. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'Amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, McLeod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C: Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002;60(suppl 1):1-6.
13. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR: National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003;95:981-989.
14. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ Jr, Miller DW, Adams JA, Shipley WU: Comparison of conventional-dose versus high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005;294:1233-1239.
15. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I: Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002;53:1097-1105.
16. Hanks GE, Pajak TF, Porter A, Grignon D, Brereton H, Venkatesan V, Horwitz EM, Lawton C, Rosenthal SA, Sandler HM, Shipley WU: Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972-3978.
17. Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C: Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005;6:841-850.
18. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D: Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001;50:1243-1252.
19. D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW: 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821-827.
20. DeWeese TL: Radiation therapy and androgen suppression as treatment for clinically localized prostate cancer: the new standard? JAMA 2004;292:864-866.
21. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F: The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 2004;171:1137-1140.
22. Catton C, Gospodarowicz M, Mui J, Panzarella T, Milosevic M, McLean M, Catton P, Warde P: Clinical and biochemical outcome of conventional dose radiotherapy for localized prostate cancer. Can J Urol 2002;9:1444-1452; discussion 1453.
23. Zietman AL, Chung CS, Coen JJ, Shipley WU: 10-year outcome for men with localized prostate cancer treated with external radiation therapy: results of a cohort study. J Urol 2004;171:210-214.
24. Lukka H, Hayter C, Julian JA, Warde P, Morris WJ, Gospodarowicz M, Levine M, Sathya J, Choo R, Prichard H, Brundage M, Kwan W: Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol 2005;23:6132-6138.
25. Cavanaugh SX, Kupelian PA, Fuller CD, Reddy C, Bradshaw P, Pollock BH, Fuss M: Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy: prognostic value of a time-and-PSA threshold model. Cancer 2004;101:96-105.
26. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA: High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 2002;53:1111-1116.
27. Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J: Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Int J Radiat Oncol Biol Phys 2005;62:1322-1331.
28. Hill RP, Rodemann HP, Hendry JH, Roberts SA, Anscher MS: Normal tissue radiobiology: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 2001;49:353-365.
29. Fowler JF, Ritter MA, Chappell RJ, Brenner DJ: What hypofractionated protocols should be tested for prostate cancer? Int J Radiat Oncol Biol Phys 2003;56:1093-1104.
30. Lock M, Catton C: High-precision radiotherapy: where are we going and how do we get there? Can J Urol 2006;13(suppl):234-236.
31. Fellows GJ, Clark PB, Beynon LL, Boreham J, Keen C, Parkinson MC, Peto R, Webb JN: Treatment of advanced localised prostatic cancer by orchiectomy, radiotherapy, or combined treatment. A Medical Research Council Study. Urological Cancer Working Party - Subgroup on Prostatic Cancer. Br J Urol 1992;70:304-309.
32. Labrie F, Cusan L, Gomez JL, Belanger A, Candas B: Long-term combined androgen blockade alone for localized prostate cancer. Mol Urol 1999;3:217-226.
33. Mason M, Warde P, Sydes M, Cowan R, James N, Kirkbride P, Langley R, Latham J, Moynihan C, Anderson J, Millet J, Nutall J, Moffat L, Parulekar W, Parmar M: Defining the need for local therapy in locally advanced prostate cancer: an appraisal of the MRC PR07 study. Clin Oncol (R Coll Radiol) 2005;17:217-218.
34. Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A: Role of prostate dose escalation in patients with greater than 15% risk of pelvic lymph node involvement. Int J Radiat Oncol Biol Phys 2005;61:695-701.
35. Cheung R, Tucker SL, Dong L, Kuban D: Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:1234-1240.
36. Asbell SO, Krall JM, Pilepich MV, Baerwald H, Sause WT, Hanks GE, Perez CA: Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988;15:1307-1316.
37. Roach M 3rd, DeSilvio M, Valicenti R, Grignon D, Asbell SO, Lawton C, Thomas CR Jr, Shipley WU: Whole-pelvis, 'mini-pelvis', or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial. Int J Radiat Oncol Biol Phys 2006;66:647-653.
38. Cavey ML, Bayouth JE, Colman M, Endres EJ, Sanguineti G: IMRT to escalate the dose to the prostate while treating the pelvic nodes. Strahlenther Onkol 2005;181:431-441.
39. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520.
40. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512.